Case-Based Modules > Case 11 > Conclusion
Great job! This was a challenging case from a management perspective. The patient developed symptomatic vasospasm, but the presence of a second aneurysm could have limited our ability to treat this.
Her cardiac function, perhaps secondary to an OMI, also could've limited our options. This case is a great example of how it's important to recognize and appreciate the multiple organ system dysfunction and how treating one organ can negatively impact the other, sometimes resulting in an overall net negative result.
Pearl 1: Radiographic vasospasm is common, but doesn't necessarily require intervention unless there are clinical manifestations.
Clinical manifestations of vasospasm are more easily recognized when they're very clearly focal. For example, if a patient suddenly becomes aphasic, and we find severe left MCA vasospasm on vessel imaging.
However, we can't forget that a diminished level of consciousness can also indicate either basilar vasospasm or bilateral anterior circulation vasospasm.
Pearl 2: Clinical vasospasm can be treated with endovascular rescue therapy or BP augmentation.
We don't know definitively whether treatment with endovascular therapy or BP augmentation improves functional outcomes. The available data is promising, but further investigation is needed.
As long as patient circumstances allow it, it is worthwhile to try one or both of these options when considering the downsides of not pursuing therapy.
Suggested Reading from this Case:
- Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association/American Stroke Association [published correction appears in Stroke. 2023 Dec;54(12):e516. doi: 10.1161/STR.0000000000000449.]. Stroke. 2023;54(7):e314-e370. doi:10.1161/STR.0000000000000436
- Lakhal K, Hivert A, Alexandre PL, et al. Intravenous Milrinone for Cerebral Vasospasm in Subarachnoid Hemorrhage: The MILRISPASM Controlled Before-After Study. Neurocrit Care. 2021;35(3):669-679. doi:10.1007/s12028-021-01331-z
- Post R, Germans MR, Tjerkstra MA, et al. Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial. Lancet. 2021;397(10269):112-118. doi:10.1016/S0140-6736(20)32518-6
- Shi M, Yang C, Chen ZH, Xiao LF, Zhao WY. Efficacy and Safety of Tranexamic Acid in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Surg. 2022;8:790149. Published 2022 Jan 10. doi:10.3389/fsurg.2021.790149